Nanoformulated phytochemicals for PCOS: therapeutic potential, translational challenges, and future perspectives

A coplex endocrine and metabolic condition, polycystic ovarian syndrome (PCOS) primarily affects women between the ages of 15 and 35. PCOS is a complex metabolic and endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and/or polycystic ovarian morphology. It often coexists with insulin resistance, oxidative stress, and low-grade of inflammation. Conventional therapies are frequently linked with negative side effects and have limited efficacy. Recent advances in nanotechnology have prompted scientists to begin developing nano-phytochemical delivery systems. In this process, bioactive plant components are nanoencapsulated into nanostructured carriers, which holds great potential as a novel PCOS treatment. The medicinal potential of nano-phytochemicals with anti-inflammatory, anti-androgenic, insulin-sensitizing, and antioxidant qualities is examined in this narrative review. By improving the solubility, bioavailability, pharmacokinetics, and targeted delivery of these phytochemicals, nanoformulation technologies increase their therapeutic efficacy. From a mechanistic perspective, nano-phytochemicals control important molecular pathways. In preclinical models, novel nanocarrier systems like nano-phytosomes, nanoemulsions, nanoparticles, and nanoethosomes have shown promise in improving metabolic profiles, reestablishing hormonal balance, and reducing ovarian dysfunction. Although these developments are encouraging, issues with safety validation, standardization, and legal frameworks still exist. Well-planned clinical trials and the creation of customized nano-phytochemical treatments suited to the variability of PCOS are necessary future directions. Overall, nanoformulated phytochemicals represent a promising but still insufficiently validated approach for PCOS management. By improving the solubility, stability, bioavailability, and delivery of selected phytochemicals, nanoformulations may help address some pharmacokinetic limitations of conventional phytochemical approaches. However, their ability to improve clinically meaningful reproductive and metabolic outcomes, reduce adverse effects, or outperform standard therapies remains to be established through rigorous pharmacokinetic, safety, and clinical studies.